TGF-β treatment of non-CF AECs reduced both CaCC and CFTR-dependent chloride currents and caused a reduction in CFTR and transmembrane member 16A (TMEM16A) protein levels. This evidence concerns the gene TGFB1 and cystic fibrosis.